Infection risk after orthopedic surgery in patients with inflammatory rheumatic diseases treated with immunosuppressive drugs

Arthritis Care and Research

Volumn 65, Issue 12, 2013, Pages 2032-2040

  Scherrer, Catrina B ^a   Mannion, Anne F ^a   Kyburz, Diego ^b   Vogt, Markus ^a   Kramers De Quervain, Inès A ^a  

^a SCHULTHESS CLINIC   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; RITUXIMAB; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; ELBOW; FEMALE; FOOT SURGERY; HAND SURGERY; HIP SURGERY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RATE; INFECTION RISK; INFECTIOUS ARTHRITIS; INFLAMMATORY RHEUMATIC DISEASE; JOINT SURGERY; KNEE SURGERY; MAJOR CLINICAL STUDY; MALE; ORTHOPEDIC SURGERY; OUTCOME ASSESSMENT; POSTOPERATIVE INFECTION; PREOPERATIVE CARE; RETROSPECTIVE STUDY; RHEUMATIC DISEASE; SHOULDER SURGERY; SPINE SURGERY; SURGICAL INFECTION;

AGED; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INFECTION; MALE; MIDDLE AGED; ORTHOPEDIC PROCEDURES; POSTOPERATIVE COMPLICATIONS; RHEUMATIC DISEASES; RISK FACTORS;

EID: 84889063167     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22077     Document Type: Article

References (39)

1. Blom AW, Taylor AH, Pattison G, Whitehouse S, Bannister GC,. Infection after total hip arthroplasty: the Avon experience. J Bone Joint Surg Br 2003; 85: 956-9.
2. Kadono Y, Yasunaga H, Horiguchi H, Hashimoto H, Matsuda S, Tanaka S, et al. Statistics for orthopedic surgery 2006-2007: data from the Japanese Diagnosis Procedure Combination database [editorial]. J Orthop Sci 2010; 15: 162-70.
3. Sia IG, Berbari EF, Karchmer AW,. Prosthetic joint infections [review]. Infect Dis Clin North Am 2005; 19: 885-914.
4. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE,. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46: 2287-93.
5. Poss R, Thornhill TS, Ewald FC, Thomas WH, Batte NJ, Sledge CB,. Factors influencing the incidence and outcome of infection following total joint arthroplasty. Clin Orthop Relat Res 1984; 182: 117-26.
6. Bongartz T, Halligan CS, Osmon DR, Reinalda MS, Bamlet WR, Crowson CS, et al. Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum 2008; 59: 1713-20.
7. Chesney D, Sales J, Elton R, Brenkel IJ,. Infection after knee arthroplasty a prospective study of 1509 cases. J Arthroplasty 2008; 23: 355-9.
8. Schrama JC, Espehaug B, Hallan G, Engesaeter LB, Furnes O, Havelin LI, et al. Risk of revision for infection in primary total hip and knee arthroplasty in patients with rheumatoid arthritis compared with osteoarthritis: a prospective, population-based study on 108,786 hip and knee joint arthroplasties from the Norwegian Arthroplasty Register. Arthritis Care Res (Hoboken) 2010; 62: 473-9.
9. Bibbo C, Anderson RB, Davis WH, Norton J,. Complications in rheumatoid foot and ankle reconstructive surgery: analysis of 718 procedures in 103 patients. Foot Ankle Int 2003; 24: 40-4.
10. Grennan DM, Gray J, Loudon J, Fear S,. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 2001; 60: 214-7.
11. Pieringer H, Stuby U, Biesenbach G,. Patients with rheumatoid arthritis undergoing surgery: how should we deal with antirheumatic treatment? [review]. Semin Arthritis Rheum 2007; 36: 278-86.
12. Choy EH, Panayi GS,. Cytokine pathways and joint inflammation in rheumatoid arthritis [review]. N Engl J Med 2001; 344: 907-16.
13. Bazzani C, Filippini M, Caporali R, Bobbio-Pallavicini F, Favalli EG, Marchesoni A, et al. Anti-TNFα therapy in a cohort of rheumatoid arthritis patients: clinical outcomes. Autoimmun Rev 2009; 8: 260-5.
14. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy study. Arthritis Rheum 2005; 52: 1020-30.
15. St.Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al, for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432-43.
16. Gorman JD, Sack KE, Davis JC Jr,. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med 2002; 346: 1349-56.
17. Bernatsky S, Habel Y, Rahme E,. Observational studies of infections in rheumatoid arthritis: a metaanalysis of tumor necrosis factor antagonists. J Rheumatol 2010; 37: 928-31.
18. Bibbo C, Goldberg JW,. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-α inhibition therapy. Foot Ankle Int 2004; 25: 331-5.
19. Den Broeder AA, Creemers MC, Fransen J, de Jong E, de Rooij DJ, Wymenga A, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 2007; 34: 689-95.
20. Hayata K, Kanbe K, Chiba J, Nakamura A, Inoue Y, Hobo K,. Clinical factors related to the efficacy and complications of orthopedic surgery for rheumatoid arthritis with infliximab. Int J Rheum Dis 2011; 14: 31-6.
21. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Ustianowski AP, Helbert M, et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70: 1810-4.
22. Giles JT, Bartlett SJ, Gelber AC, Nanda S, Fontaine K, Ruffing V, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 2006; 55: 333-7.
23. Kawakami K, Ikari K, Kawamura K, Tsukahara S, Iwamoto T, Yano K, et al. Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-α blockers: perioperative interruption of tumour necrosis factor-α blockers decreases complications? Rheumatology (Oxford) 2010; 49: 341-7.
24. Momohara S, Kawakami K, Iwamoto T, Yano K, Sakuma Y, Hiroshima R, et al. Prosthetic joint infection after total hip or knee arthroplasty in rheumatoid arthritis patients treated with nonbiologic and biologic disease-modifying antirheumatic drugs. Mod Rheumatol 2011; 21: 469-75.
25. Gilson M, Gossec L, Mariette X, Gherissi D, Guyot MH, Berthelot JM, et al. Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α- blockers: a case-control study. Arthritis Res Ther 2010; 12: R145.
26. Ruyssen-Witrand A, Gossec L, Salliot C, Luc M, Duclos M, Guignard S, et al. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor α blockers. Clin Exp Rheumatol 2007; 25: 430-6.
27. Goh L, Jewell T, Laversuch C, Samanta A,. Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A systematic review of the evidence [review]. Rheumatol Int 2012; 32: 5-13.
28. Ding T, Ledingham J, Luqmani R, Westlake S, Hyrich K, Lunt M, et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford) 2010; 49: 2217-9.
29. Nederlandse Vereniging voor Reumatologie. Medicijnen: het toepassen van TNF blokkade in de behandeling van reumatoide artritis. Utrecht: Dutch Society for Rheumatology; 2003.
30. Dixon WG, Carmona L, Finckh A, Hetland ML, Kvien TK, Landewe R, et al. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Ann Rheum Dis 2010; 69: 1596-602.
31. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR, and the Hospital Infection Control Practices Advisory Committee. Guideline for prevention of surgical site infection, 1999. Infect Control Hosp Epidemiol 1999; 20: 250-78.
32. Trampuz A, Zimmerli W,. Diagnosis and treatment of implant-associated septic arthritis and osteomyelitis. Curr Infect Dis Rep 2008; 10: 394-403.
33. Peel TN, Buising KL, Choong PF,. Diagnosis and management of prosthetic joint infection. Curr Opin Infect Dis 2012; 25: 670-6.
34. Heinze G, Juni P,. An overview of the objectives of and the approaches to propensity score analyses. Eur Heart J 2011; 32: 1704-8.
35. Blackstone EH,. Comparing apples and oranges. J Thorac Cardiovasc Surg 2002; 123: 8-15.
36. Kaandorp CJ, van Schaardenburg D, Krijnen P, Habbema JD, van de Laar MA,. Risk factors for septic arthritis in patients with joint disease: a prospective study. Arthritis Rheum 1995; 38: 1819-25.
37. Young MH, Washer L, Malani PN,. Surgical site infections in older adults: epidemiology and management strategies [review]. Drugs Aging 2008; 25: 399-414.
38. Achermann Y, Vogt M, Spormann C, Kolling C, Remschmidt C, Wust J, et al. Characteristics and outcome of 27 elbow periprosthetic joint infections: results from a 14-year cohort study of 358 elbow prostheses. Clin Microbiol Infect 2011; 17: 432-8.
39. Reeves CL, Peaden AJ, Shane AM,. The complications encountered with the rheumatoid surgical foot and ankle [review]. Clin Podiatr Med Surg 2010; 27: 313-25.